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Abstract
Annually, adverse drug reactions result in more than 2,000,000 hospitalizations and rank among the top 10 causes of death
in the United States. Consequently, there is a need to continuously monitor and to improve the safety assessment of
marketed drugs. Nonetheless, pharmacovigilance practice frequently lacks causality assessment. Here, we report the case of
flupirtine, a centrally acting non-opioid analgesic. We re-evaluated the plausibility and causality of 226 unselected,
spontaneously reported hepatobiliary adverse drug reactions according to the adapted Bradford-Hill criteria, CIOMS score
and WHO-UMC scales. Thorough re-evaluation showed that only about 20% of the reported cases were probable or likely
for flupirtine treatment, suggesting an incidence of flupirtine-related liver injury of 1: 100,000 when estimated prescription
data are considered, or 0.8 in 10,000 on the basis of all 226 reported adverse drug reactions. Neither daily or cumulative
dose nor duration of treatment correlated with markers of liver injury. In the majority of cases (151/226), an average of 3 co-
medications with drugs known for their liver liability was observed that may well be causative for adverse drug reactions,
but were reported under a suspected flupirtine ADR. Our study highlights the need to improve the quality and standards of
ADR reporting. This should be done with utmost care taking into account contributing factors such as concomitant
medications including over-the-counter drugs, the medical history and current health conditions, in order to avoid
unjustified flagging and drug warnings that may erroneously cause uncertainty among healthcare professionals and
patients, and may eventually lead to unjustified safety signals of useful drugs with a reasonable risk to benefit ratio.
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Introduction
Despite the vigorous and extensive safety testing during the drug
development process rare adverse drug reactions (ADRs) of new
medicinal products can not be detected at the time of market
introduction. Consequently, ADRs are a leading cause for market
removal of drugs [1–4] with drug-induced toxicities ranking
among the top 10 causes of death in the US to result in health care
costs of $30 billion US Dollars annually [5,6]. Here, drug-induced
liver injury (DILI) is the most frequent ADR and accounts for
more than 50% of all cases of acute liver failure in the United
States today [7].
As drug approvals are based on studies in 3,000–6,000 patients or
less ADRs occurring in about 1 in 10000 patients cannot be detected
in development programs. In addition, clinical study populations are
inevitably pre-selected by study protocol-defined in- and exclusion
criteria and are therefore not representative for the entire patient
population exposed after market introduction. Therefore, prevention
of ADRs remains the challenge of post-authorisation safety
surveillance and it was estimated that approximately 600,000 subjects
(1% of the population) exposed for one year would be required in
order to reliably detect rare ADRs [8].
To overcome the safety gap between clinical studies and marketed
products, pharmacovigilance aims to monitor, detect, understand
and prevent ADRs (Table 1). Furthermore and as part of the FDA
Post Marketing Drug Risk Assessment (PMDRA) program, pharma-
ceutical companies are requested to maintain a post-marketing
surveillance system to provide Periodic Safety Update Reports
(PSUR). Overall, national and international institutions gather a
tremendous amount of data that necessitates data base entry and
management, standardization procedures, statistical strategies and
further processing and evaluation of the data. While pharmacov-
igilance databases can be used for the detection of early signals and
may deliverevidence-based safetyinformation for regulatorydecision
making [9], critical examination, along with careful interpretation
and causality assessment of ADR data is required to eventually
improve currently established drug safety concepts.
Here, we address some challenges and limitations of current
pharmacovigilance practice and processes. We choose the
analgesic flupirtine as an example and evaluated the spontaneous
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25221ADR reports that led in Germany to a signal of hepatotoxicity.
Using this drug as an example we wish to highlight the potential
pitfalls and limitations in drug safety evaluation of ADR reports
and to stimulate a discussion on improved ADR reporting and
assessment.
An evaluation of spontaneous reports on suspected adverse
reactions kindly provided by the German health authority (BfArM)
and the Drug Commission of the German Medical Association is
presented to probe for the evidence of adverse hepatobiliary events
reported in association with the administration of the analgesic
flupirtine. Specifically, flupirtine is a central non-opioid analgesic
with muscle-relaxing properties, which is classified as a first in class
Selective Neuronal Potassium (KCNQ) Channel Opener
(SNEPCO) [10,11].
Since its approval in Germany in 1984 flupirtine serves as an
alternative for non-steroidal anti-inflammatory drugs (NSAIDs)
and cyclooxygenase-2 (COX-2) inhibitors primarily for the
treatment of pain associated with degenerative changes of the
musculoskeletal system and conditions associated with painful
muscle tension or spasms (e.g. lumbalgia). Flupirtine provides
analgesia without cardiac, renal and gastrointestinal adverse
effects, including bleeding complications, and others that limit
the therapeutic use of NSAIDs in pain management. Moreover,
flupirtine separates from typical side-effects profile of opioids such
as respiratory depression potential or constipation.
Prescriptions numbers for flupirtine continue to rise with
approximately 17 millions defined daily doses in 2006, an increase
of about 40% compared to the previous year [12].
In 2007 the Drug Commission of the German Medical
Association (AkdA ¨) released a notification on the hepatotoxic
potential of flupirtine that was based on ADRs reported over a
16-year period (1992–2007). Concern was expressed that the
incidence of flupirtine-related liver injury may have been
underestimated. Thus, the signal ‘‘hepatobiliary ADR/liver
toxicity’’, which was detected only by number of reports but not
by plausibility test of causality evaluation of spontaneous reports,
was communicated as a signal for a possible general hepatotoxicity
of flupirtine [13].
In the following we present the results of a standardized Medical
Dictionary for Regulatory Activities (MedDRA) query and the
evaluation of individual spontaneous reports in order to verify
whether or not the signal ‘‘hepatobiliary ADR/liver toxicity’’, is
substantiated and reproducible in the majority of individual ADR
cases. Our thorough analysis of all reported cases yielded no
evidence for flupirtine to qualify as liver toxin.
Methods
A standardized MedDRA query for reports of hepatobiliary
adverse events in association with flupirtine treatment was carried
out using the German health authority (BfArM) data base for
suspected adverse drug reactions in February 2009.
The query retrieved a total of 229 reports, of which 3 cases were
excluded since they were reported twice. Cases were assessed using
the WHO-UMC causality assessment system (www.who-umc.org)
and the adapted Bradford-Hill criteria [14,15]. The Council for
International Organizations of Medical Sciences/Roussel Uclaf
Causality Assessment Method scale (CIOMS score), as discussed
by Teschke et al., 2008 [16], was used as reference scale. Statistical
correlations were based on linear regression analysis using the
Statistica software, Version 8.0 (Statsoft Inc., Tulsa, USA). Data
sets used for statistical evaluations are provided as supplementary
material (Table S1).
Based on prescription numbers for the years 1992–2008 that
amounted to defined daily doses (DDD) of 155.2 millions with a
median drug intake of 56 days (estimated from n=175 of 226
cases, where information on duration of drug intake was available),
the incidence of flupirtine-related hepatobiliary adverse events was
estimated to be about 0.8 in 10,000 patients. This is considered to
be a very rare frequency of hepatobiliary ADRs that was
calculated the following way:
a)
DDD
Median treatment duration
~Estimated number of patients
155,2|106 DDD
56 days
~2,77|106 patients
b)
Number of ADR cases
Estimated number of patients
~x incidence in 10,000
Table 1. Aims of post-marketing drug safety (pharmacovigilance) information reporting and management (adapted from Bate A
et al., 2008 [28]).
Aims of pharmacovigilance
Signal detection To detect previously unknown adverse drug effects after drug approval
Discovery of subgroup at risk To evaluate risks in subpopulations (based on age, sex, main diagnosis and disease)
Estimation of ADR incidence To estimate all of adverse drug reactions in relation to additional information such as sales volume
(provided by manufacturers)
Support of risk-benefit analyses To estimate the risk of potentially toxic drugs and compare it to their beneficial therapeutic potential
Discovery of potential drug-drug interactions To detect previously unknown drug-drug interactions and to estimate incidences of known drug-drug
interactions
Hypotheses generation for off-target drug effects To propose mechanisms of ADRs based on prospective or retrospective analysis of clinical data
Risk management strategies Strategies and recommendations for an identification of individuals at risk to improve safety of drugs
doi:10.1371/journal.pone.0025221.t001
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2,77|106 patients
~0,8 in 10,000
Results
Spontaneously reported hepatobiliary reactions related
to flupirtine exposure
In the years 1992–2008 a total of 226 spontaneous individual
reports of hepatobiliary adverse events related to flupirtine
exposure were notified to and recorded by the German Federal
Institute for Drugs and Medical Devices (BfArM). The majority of
the reports were provided by healthcare professionals; others were
reported by the marketing authorisation holder of flupirtine,
clinical study directors and patients. Some basic demographic
information on sex and age of the cohort is provided in Table 2.
About 76% of 226 patients were female (for 3 patients no
gender information was available), and the age of most patients
was between 40 to 60 years (56%) or older (35%). The sex
distribution agrees well with registered prescriptions, i.e. 33.3% for
male and 66.7% for female patients for the years 1992–2008
according to IMS Health Incorporated data. Six cases with a fatal
outcome were reported in association with flupirtine administra-
tion. The median daily dose of flupirtine was reported with
300 mg and the median duration of exposure was 56 days.
Numbers of annually reported cases are provided in Figure 1.
Correlation versus causation
To evaluate the causality of drug exposure for a reported
suspected ADR, the data have to be probed for their statistical
association and for the validity, reliability and consistency of the
reported evidence [17–19]. The theoretical basis for an assessment
of a causal relationship evaluation between two factors was
established by Sir Austin Bradford-Hill in 1965 [15]. These
criteria include strength, consistency, specificity, temporality,
biological gradient, plausibility, coherence, experimental evidence
and analogy. Since then, the Bradford-Hill criteria have been
widely used in epidemiology and may be, with some limitations,
applied to pharmacovigilance and pharmacoepidemiology as well
[14]. A summary of the adapted Bradford-Hill criteria applied to
the pharmacovigilance data base obtained from the German
Federal Institute for Drugs and Medical Devices (BfArM) for
flupirtine is given in Table 3. The findings in Table 3 will be
discussed in conjunction with an evaluation based on the CIOMS
and WHO-UMC causality assessment system described below (see
also supplementary Table S4 for a classification of the severity of
the ADR cases according to who-umc.org).
Figure 2 displays scatter blots of the laboratory parameters
aspartate aminotransferase (AST) (Figure 2A), alanine aminotrans-
ferase (ALT) (Figure 2B) and bilirubin (Figure 2C) (in6upper limit
of normal (ULN)) in relation to daily dose of flupirtine, cumulative
dose,aswell as time toonset(TTO)ofthe suspected ADR.Statistical
analyses did not evidence any significant relationship between the
respective parameters (see Figure 2). Size of data sets and p-values
are provided as supplementary material (Tables S2 and S3).
Plausibility check based on history of drug intake
(pharmacoanamnesis)
Step wise exclusion of alternative causes for the reported
adverse drug events is part of an aetiology based approach for a
causal assessment of ADRs, such as the ‘‘French approach’’
[20,21]. Likewise, an application of the Bradford-Hill criteria for
the plausibility of the causal relation between drug and event
involves exclusion of alternative aetiologies affecting the hepato-
biliary system, such as infections (viral, bacterial, parasites),
metabolic diseases (e.g. non-alcoholic steatohepatitis), storage
diseases (M. Wilson, haemochromatosis), auto-immune diseases,
other systemic diseases (lupus erythematodes, chronic inflamma-
tory bowels disease amongst others). Table 4 lists the information
reported on exclusion of viral and autoimmune-related causes of
hepatobiliary symptoms reported as suspected ADRs of flupirtine.
Information on exclusion of other hepatotropic viruses was
provided in a few cases only. For 26 patients test results were
reported for EBV (in 24 cases), CMV (13 cases) and VZV (5 cases).
No cases with hepatitis E infection were reported.
There were 22 reported cases of alcohol abuse and 11 cases of
diabetes mellitus that had been suspected as possible confounders
for the observed liver toxicity during flupirtine therapy.
To evaluate the hepatic safety profile of flupirtine, co-
medications needed to be assessed as well. Out of 167 cases
(73.9% of all 226 cases) with reported co-medication 151 cases
(90.4% of 167 cases) received co-medication that included one or
more medicines labelled for ADRs affecting the hepatobiliary
system (summary of product characteristics (SmPC) contained
information on hepatobiliary ADRs).
The median number of additional co-medications with the
potential for hepatobiliary ADRs was two with a large scatter
(average: 2.863.1). In 51 out of 167 cases notified, the reporter
had suggested the co-medications as a possible cause of the
suspected adverse reaction. Table 5 provides an overview of the 10
most common co-medications in the ADR reports on flupirtine
labelled for hepatobiliary ADRs. The 10 most common co-
medications suspected for a causal/contributing relation to the
reported ADRs with flupirtine are listed in Table 6.
In the following two case reports are briefly described where
flupirtine was rated as either unlikely or certain for ADR.
Case report 1. While hospitalized, a 32-year old male patient
diagnosed with Guillain Barre Syndrome had received flupirtine,
ibuprofen, and metamizole as pain medication. Reported co-
medications were: pregabalin, insulin, promethazine, enoxaparin
and potassium citrate. After 3 days of flupirtine administration
(600 mg/day) he displayed increased ALT (46ULN) and AST
levels (36ULN). Treatment with flupirtine and pregabalin was
discontinued. With a latency of 6 days he was re-exposed to
Table 2. Sex and age distribution in 226 cases of
spontaneously reported suspected ADRs to the German
Federal Institute for Drugs and Medical Devices.
No. of cases [%]
Sex of patients
Total cases 226 100
Female patients 171 76
Male patients 52 23
No information 3 1
Age distribution
,40 years 3 1
40–60 years 126 56
.60 years 80 35
No information 18 8
doi:10.1371/journal.pone.0025221.t002
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(286ULN) and AST (246ULN) levels. Drug-induced liver injury
– induced by pregabalin was rated certain.
As described above the 226 cases also included cases, where co-
medications rather than concomitant diseases (hepatitis) were more
likely to be responsible for the hepatobiliary ADR. Specifically, in
case no. 1 re-challenge with pregabalin led to a massive increase of
serum transaminases. This case can therefore be rated as unlikely
for flupirtine exposure to cause DILI. In contrast, in case no. 2 (see
below) and due a positive re-challenge with flupirtine the reported
ADR was rated to be ‘‘certain’’ (WHO/UMC system) or ‘‘possible’’
(CIOMS score). The difference in the score between both causality
assessment systems is related to the lack of clinical information for
case no. 2 (e.g. other than viral causes), which have a higher weight
in the CIOMS score.
Case report 2. A 53-year-old female patient was admitted to
the hospital and diagnosed with jaundice. Viral and autoimmune
hepatitis were excluded. The patient had taken flupirtine on
demand (unknown daily dose) for the treatment of pain related to
cervical spine syndrome. The patient displayed increased
transaminases (ALT: 31.06ULN, AST: 19.86ULN). Co-
medications were estradiol+norethisterone and zolpidem on
demand. After discontinuation of flupirtine the lab parameters
decreased. Re-exposure (dose unknown) on day 5 of admission
resulted in a recurrent increase of laboratory parameters (see
Figure 3 below).
A systematic review of the 226 spontaneous individual reports of
hepatobiliary ADRs associated with flupirtine intake defined 57
cases with elective liver biopsies. However, information on liver
biopsies for 49 cases could be retrieved only and the findings are
summarised in Table 7 (note, for each case several diagnoses are
listed). Essentially for 23 cases inflammatory hepatitis was
confirmed by histopathology while histopathological features
consistent with toxic liver damage were reported for 36 cases.
Furthermore, in 29 out of the 36 cases (i.e. .80%) with toxic liver
damage, co-medications with other drugs known to cause
hepatobiliary ADRs were reported as well and in n=6 cases
autoimmune-related changes were excluded, but in 18 of the 226
patients positive titres for auto antibodies were noted.
Neither anti-nuclear antibodies (ANAs) nor anti-mitochondrial
antibodies (AMAs) are sufficiently specific for the diagnosis of an
autoimmune liver disease. Positive titres for these are also found in
other conditions, such as collagenosis, rheumatoid arthritis, as well
as primary biliary cirrhosis, which could however be excluded,
based on the available histopathology findings. Furthermore, in
one case the liver specific protein (LSP) was determined, but
reported as negative.
Findings from re-challenge of individual patients
To further probe for a possible causal relationship of
hepatobiliary ADRs patients may be re-challenged with the
suspected drug. However, this constitutes significant risks for the
patient and should only be attempted if the drug is required to
treat a serious disease and no alternative medication is available.
In the present study and mainly due to medically unsupervised re-
exposure by the patients themselves, information on liver
transaminases was obtained. Out of 226 cases with hepatobiliary
ADRs, re-challenge was reported in 15 cases with information on
the outcome available for n=14 cases (6.2% of 226 cases). In
n=13 cases (5.8% of 226 cases) re-challenge resulted in a re-
occurrence or worsening of the symptoms, while in 1 case no
increase of transaminases was observed.
Apart from these well defined cases the following assumption
may be justified. In 59 out of 226 cases no information on co-
medication was available but at least for 32 of these 59 cases (or
14.2% of 226 cases), an amelioration of symptoms upon
treatment discontinuation (positive de-challenge) was observed.
The lack of additional information does not permit firm
conclusions to be drawn from these cases which are confounded
by the likely use of additional but unreported pain medications.
Thus, the positive de-challenge may simple result from the
complete withdrawal of all drugs used in the pain management of
these patients.
Generally, a positive re-challenge results in an increase of
transaminases after re-exposure with a suspected drug and this
indicates a likely causal relationship, provided other potential
causes can be excluded with sufficient certainty (see case report
2).
Figure 1. Annually reported cases of flupirtine induced liver injury. Annually spontaneously hepatobiliary adverse events reported for
flupirtine (black) and proportion of cases rated to be ‘highly probable’ or ‘probable’ according to the CIOMS score (grey).
doi:10.1371/journal.pone.0025221.g001
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WHO-UMC scales
The results of the evaluation based on the CIOMS scale and the
WHO-UMC causality assessment system are provided in Table 8.
After subtracting 36 reports witch lacked essential information,
190 cases were analyzed for possible aetiologies according to
WHO-UMC causality assessment system [8,9,14,18,19]. Causality
assessment rated 14 cases to be certain, 19 cases to be probable,
124 cases to be possibly and 33 cases to be unlikely associated with
flupirtine treatment. The result for each case was compared with
an evaluation according to the CIOMS scale. Both classifications
agreed by about 55%. 176 cases of reported suspected ADRs rated
by the WHO-UMC causality assessment system did not provide a
certain (93% of 190 included cases) and 157 cases (83%) not a
probable link to flupirtine intake. Thus, the majority of cases was
not rated likely (highly probable) or probably related to flupirtine
Table 3. Causality assessment according to the adapted Bradford-Hill criteria.
Criteria Findings Evidence
Strength of association No statistical association between dose/duration
& exposure of flupirtine and response in
laboratory parameters ALT, AST, bilirubin
(see Figure 1) or alkaline phosphatase (AP)
ADR incidence below 1% [23,29–35] – Long-term controlled open
tolerability study for 12 months (n=244 patients): according to
laboratory values no effects on liver function (DD 100–600 mg) [26].
Consistency of association Clinical studies: At least 6 published clinical
trials at the Pubmed database; Literature
reports do not provide evidence for
hepatobiliary side effects
various reports on the pharmacokinetics and metabolism of flupirtine
[36–38] – e.g. 1 report on a putative protective mechanism on
mitochondria (liver) [39].
- e.g. various reports on anti-apoptotic and neuroprotective activities [40–44]
e.g. 1 report on use in patients with impaired liver function [35]
Dose-Response Relationship No statistically significant correlation between
the daily and cumulative dose and the clinical
chemistry parameters ALT, AST and bilirubin
[for analysis see supplementary data]
Number of cases in direct temporal relationship (,14 days:)
30/176 cases, thereof are 9/176 cases with time relation #2 days,
12/176 cases with time relation .2a n d#7 days and 9/176 cases
with time relation .7a n d,14 days
Temporal Relationship No information regarding the time to onset
of ADR in 50/226 cases
Number of cases with a possible temporal relationship: 17/176
cases with time relation 14–30 days
Number of cases with no direct temporal relationship (.30 and
,365 days): 121/176 cases [for analysis see supplementary data]
Number of cases with an unlikely temporal relationship: 8/176
cases with a time relation .365 days
Number of cases where cessation of adverse
events (AE) after discontinuation of treatment
was reported: 164/22
98/164 positive dechallenge
66/164 unclear dechallenge
10/66 very slow decrease of laboratory parameters
56/66 decrease of laboratory parameters after discontinuation
of flupirtine and at least one other potential hepatotoxic drug
Number of cases where cessation of AE after
discontinuation of treatment was not
reported 62/226
6/62 could not be evaluated due to death of the patients
49/62 no information available
7/62 dechallenge did not resolve condition (causality unlikely)
Coherence/Specificity At total of 23/226 cases with reported re-exposure
A total of 14/23 with reported outcome 13/14 positive re-challenge result (causality assumed)
1/14 negative re-challenge result (no causality assumed)
A total of 167/226 cases with reported
co-medications
151/167 cases where co-medication(s) could be responsible
or contributing factor(s) for hepatobiliary ADRs
51/167 cases where physician explicitly suspected co-medication
to be causally involved in the reported ADR
Plausibility Exclusion of other causes, such as infections,
alcohol, disease-related causes, other drugs
(see text and Table 4)
Summary of the analyses of 226 spontaneous suspected ADRs reports.
doi:10.1371/journal.pone.0025221.t003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25221Figure 2. Results of liver function tests of spontaneously reported ADRs. Scatter plots of maximum AST (A), ALT (B), and bilirubin (C) levels
(given in6ULN) in relation to the daily dose (left panel), cumulative doses (daily dose (mg)6duration of drug exposure (days), middle panel), and in
relation to the time to onset (right panel) of the ADRs in cases of suspected hepatobiliary adverse events associated with flupirtine exposure.
doi:10.1371/journal.pone.0025221.g002
Table 4. Incidence of viral disease and cases with positive autoimmune titres in 226 cases of liver ADR linked to flupirtine
treatment.
No. of cases [% of all 226 cases]
Results for cases with autoimmune antibodies reported 50 22.1
Autoimmune antibodies positive 18 8.0
Autoimmune antibodies negative 32 14.2
Results unclear 20 . 9
No information 174 77.0
No. of cases [% of all 226 cases]
Results for cases with reported hepatitis serology 106 46.9
Hepatitis A positive (total) 19 8.4
Hepatitis A acute infection 3 1.3
Hepatitis A old infection 16 7.1
Hepatitis infection status unclear 4 1.8
Hepatitis B positive 10 . 4
Hepatitis C positive 10 . 4
doi:10.1371/journal.pone.0025221.t004
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between the two causality assessment systems. Different outcome
between various causality assessment scales has been observed by
others (as recently reported by Garcia-Cortes et al., 2008 [22]). We
view the CIOMS scale particularly useful as it addresses more
vigorously hepatobiliary ADRs.
In 6 of the reported ADR cases (2.6%) with possible/probable
causality (according to WHO/UMS assessment) to flupirtine
exposure the symptoms associated with the event were consistent
with allergic/pseudo-allergic drug reactions (acute symptoms
shortly after flupirtine administration, earlier reported exposure,
fever, rash, nausea, gastrointestinal symptoms or respiratory
distress), which are largely independent from dose [23]. The lack
of the dose-relationship and the close temporal relation to
flupirtine exposure classifies a total of 19 cases (not infectious, no
potential hepatotoxic co-medication, no other co-medication, no
autoimmune antibodies, no other causes, no alcohol, time to onset
of ADR,90 days) as possible/probable idiosyncratic type B
reactions.
As discussed above we infer monotherapy with flupirtine in 59
out of 226 cases since no other information is available. The lack
of additional information does not permit firm conclusions to be
drawn about the cases since the suggested association between
flupirtine and hepatobiliary events might be confounded by
various unreported hepatotoxic pain medications. Notably,
NSAIDs were the most common co-medication (59 of 226
cases=26.1%) in hepatobiliary ADR reports for flupirtine. Mostly,
NSAIDs were prescribed to the patients for the same indication as
flupirtine as part of a combination therapy of the underlying pain
condition. As shown in Tables 5 and 6, co-medications consisted of
numerous drugs with a potential to cause hepatobiliary ADRs or
even DILI, with one patient receiving up to 25 drugs.
Furthermore, as shown in Figures S1 and S2 of the supplementary
data, the number of drugs given and the severity of liver damage
appeared to be linked in patients suffering from a variety of pain
conditions to either the use NSAIDs or other drugs known or
suspected to be hepatotoxic.
Discussion
Pharmacovigilance aims at an understanding and the preven-
tion of adverse drug effects to enhance patient safety in relation to
the use of medicines. There is a need for reliable and balanced
information for the effective assessment of the risk-benefit profile
of medicines.
Based on these premises we repor tt h ec a s eo ff l u p i r t i n ew h e r e
limitations of causality assessment of ADR filings resulted in
distorted signal detection for DILI. A thorough analysis
provided little evidence for flupirtine to be reasonably suspected
as a candidate drug with a remarkable liability for causing
hepatotobiliary adverse events. Rather, management of pain
frequently requires complex co-medication with drugs well
known for their hepatobiliary adverse event profile, such as
NSAIDs. Our data analysis establishes that pain relief with
flupirtine does not impose a higher risk for hepatobiliary ADRs
or DILI based on the incidence that was estimated to ,1i n
10,000 as compared to NSAIDs. For instance, a recent study
estimated the incidence of severe hepatobiliary ADRs requiring
hospitalization in patients receiving the NSAID diclofenac to 23
in 100,000 patients [24,25]. Based on prescription numbers for
the years 1992–2008 that amounted to defined daily doses
(DDD) of 155.2 millions with a median drug intake of 56 days
(estimated from n=175 of 226 cases, where information on
duration of drug intake was available), the incidence of
flupirtine-related hepatobiliary adverse events was estimated to
be about 0.8 in 10,000 patients.
Table 5. The 10 most common co-medications with a
potential for hepatobiliary ADRs in n=151 reported cases
with co-medications possibly responsible or contributing
factor(s) for hepatobiliary ADRs.
No. Medication No. of cases % of 151 cases
1 Ibuprofen 19 12.6
2 ACE Inhibitors 19 12.6
3 Acetylsalicylic acid 17 11.3
4 Amitriptyline 17 11.3
5 Coxibs 16 10.6
6 Diclofenac 17 11.3
7 Tramadol 17 11.3
8 Statins 15 9.9
9 Metamizol 14 9.3
10 Estradiol 14 9.3
doi:10.1371/journal.pone.0025221.t005
Table 6. The 10 most common co-medications of n=51 cases reported by physicians as a possible cause of hepatic ADRs.
No. Medication
No. of cases reported
as suspected
No. of cases with this
drug as com-medication %
1 Amitriptyline 5 17 9.8
2 Coxibs (Rofecoxib, Lumiracoxib, Etoricoxib, Celecoxib) 5 16 9.8
3 Estradiol 4 14 7.8
4 Diclofenac 3 17 5.9
5 Doxepin 2 9 3.9
6 Fluvastatin 2 4 3.9
7 Gabapentin 2 5 3.9
8 Ibuprofen 2 19 3.9
9 Levothyroxine 2 10 3.9
10 Metamizol 2 14 3.9
doi:10.1371/journal.pone.0025221.t006
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causality or that could definitely be excluded would not be
considered in these estimates, the ‘‘true’’ (i.e. less confounded)
incidence would be even lower than the estimate given above.
The low incidence of hepatobiliary ADRs is also supported by
findings in various clinical studies, in which flupirtine was
administered over long term periods (up to 12 months) under
well controlled clinical conditions without signs of liver toxicity
[26]; [Clinical trial (1988): Investigation of the efficacy and
tolerance of the analgesic flupirtine in patients who regularly need
analgesics for long periods (uncontrolled open multicentre study),
not published]; Owner: MEDA Pharma GmbH & Co. KG, Bad
Homburg, Germany] and there are basically no published case
reports in regards to flupirtine hepatobiliary ADRs, despite a more
than 20 year-use of this drug. Note that the incidence of
hepatobiliary ADRs reported for common NSAIDs is 3 to 23
per 100,000 patients and therefore higher than that of flupirtine
[24].
Based on the pharmacovigilance data base entries, it is highly
probable that the complex co-medication with drugs labelled with
hepatobiliary ADR profiles may well be responsible for the
majority of the hepatobiliary ADRs reported for flupirtine.
Figure 3. Flupirtine hyper-sensitivity of a 53-year-old female patient. Laboratory results of a 53-year-old female patient after exposure and
re-exposure to flupirtine. She experienced icterus with markedly increased serum transaminase levels. Upon discontinuation transaminase levels
decreased. On day 6 of hospital admission re-exposure to an unknown dose of flupirtine resulted in a recurrent increase of laboratory values.
doi:10.1371/journal.pone.0025221.g003
Table 7. Histopathological findings in liver biopsies taken from n=49 patients with reported hepatobiliary ADRs (multiple
histological findings were listed for one patient).
Diagnosis Cases confirmed Cases excluded Cases possible
Cases with no
information
Toxic liver damage 3 6 001 3
Fibrotic changes 1 5 103 3
Necrotic changes 3 0 001 9
Cirrhotic changes 1 304 5
Steatotic changes 3 504 1
Cholestatic changes 1 0 703 2
Inflammatory reactions 2 3 002 6
Autoimmune related changes 0 653 8
Virus hepatitis 01 1 1 3 7
Alcohol-related changes 0 204 7
Morbus Wilson (Cu) 0 404 5
Haemochromatose (Fe) 11 2 0 3 6
Changes of the bilary duct system 2 903 8
doi:10.1371/journal.pone.0025221.t007
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idiosyncratic reactions that might occur with an incidence of less
then 1 in 100,000. This estimate is based on 19 reported cases and
.2.7 million patients that were treated with an estimated average
duration of 56 days as discussed above. In November 2007 the
Drug Commission of the German Medical Association (AkdA ¨)
released a warning for flupirtine that was followed by an apparent
increase in spontaneously reported cases in 2008. This apparent
increase in ADR reporting, however, may be more reasonably
explained by the considerable increase in prescription numbers
that occurred during that time, and perhaps also may be related to
an increase in awareness of possible hepatobiliary ADRs in
response to the warning by the medical authority, a challenging
phenomenon in drug safety assessment. Despite an increase in
crude numbers of ADR reporting in the years 2007 (kind of over-
reporting) and 2008 of more than 7-fold compared to the average
ADR reporting in earlier years, the number of cases, which were
rated ‘likely’ or ‘probably’ remained largely unchanged as depicted
in Figure 1.
Although the release of a warning raises public attention and
might have either a beneficial or confounding impact in signal
detection, it should not be taken as a substantial evidence for a
suspected adverse drug reaction without a thorough causality
assessment of each spontaneously reported case.
Impaired hepatic function in patients with primary liver diseases
or alcohol-induced liver injury (i.e. severe liver cirrhosis) are
labelled contra-indications for flupirtine, since these conditions
may predispose to CNS-related adverse reactions to flupirtine,
such as ataxia and exaggeration of symptoms of hepatic
encephalopathy.
Evaluation of the 226 ADRs identified a majority of cases that
were confounded by medical history, intercurrent diseases
involving cases of hepatic steatosis (see Table 7), abuse of alcohol
and/or drugs, and other co-medications which themselves carry
the potential of hepatobiliary ADRs. The strong association
between the number of co-medications and the reported cases of
hepatobiliary ADRs during flupirtine therapy are important for
the causality assessment. Unfortunately, the number of cases of
mono therapy with flupirtine could not be determined precisely,
simply because no reliable information was available. We therefore
assumed 59 cases on mono-therapy with flupirtine. For 32 cases an
improvement was reported after drug withdrawal that would
represent 14.2% out of 226 cases or 54% out of 59 cases.
Nonetheless, it is likely that these patients had received additional
medications (note for 167 cases co-medication was reported and in
the majority of cases (90.4% of 167 cases) co-medication included
one or more medicines labelled for ADRs affecting the
hepatobiliary system). Indeed, co-medication particularly with
drugs known to have hepatobiliary side effect profile such as
NSAIDs and antidepressants may have been either the primary
cause or at least significant contributors to liver injury also in cases
attributed to flupirtine. Pain management often requires complex
co-medications, which means that causality with regards to
hepatobiliary safety signals for a given drug needs to be assessed
in conjunction with all other parts of the treatment regimen.
Particularly elderly patients have a reduced hepatic metabolism
and renal clearance, as well as a reduced distribution volume. An
adjustment of their therapy in regard to dose and choice of drugs
has to take their increased ADR risk profile into account.
Our data show a direct link between the number of drugs given
and the severity of liver impairment suggesting that a combination
of COX-2 inhibitors or NSAIDs itself or with flupirtine may
significantly aggravate and/or increase the incidence of hepato-
biliary ADRs. This is in line with an analysis of 54,583 reports of
suspected adverse drug reactions from the French Pharmacov-
igilance database that suggested a six- to sevenfold higher risk for
severe ADRs (hepatic injury and acute renal failure) when two
NSAIDs or more were administered at the same time [27]. In light
of the well known and broad spectrum of adverse drug reactions
related to NSAIDs the high number of cases with NSAID as co-
medications is not surprising. One reason for the high number of
co-medications in some ADR reports is the possibility to obtain
drugs over the counter without prescription as part of a ‘‘self
medication plan’’. The poor awareness regarding the risk profile of
OTC drugs has been the subject of several warnings by the
regulatory authorities. In hepatobiliary ADR reports on flupirtine
drug-drug interactions, for instance with NSAIDs, appear to have
been a major contributing factor.
Current pitfalls in pharmacovigilance
Pharmacovigilance is of utmost importance to provide infor-
mation on drug exposure and safety/tolerability in a large and
inhomogeneous unselected patient population. Lack of relevant
information regarding aetiologies, medical history, and co-
medications can lead to misconceptions and distorted signals of
ADRs as summarised in Figure 4.
While data mining is of great importance for pharmacovigilance
there are unmet needs in the development of algorithms for the
reliable detection of ADR signals. Unfortunately currently used
data mining algorithms are not vigorously validated and do not
objectively screen spontaneous reported data. As of today neither
supervised nor unsupervised mathematical models are available
that can be used reliable for the causality assessment of
spontaneous reported ADRs. Furthermore, current data mining
Table 8. Evaluation of 226 cases with suspected hepatobiliary ADRs reported for flupirtine obtained with the CIOMS score and the
WHO-UMC causality assessment system.
CIOMS WHO
[No. of cases] [% of total cases] [No. of cases] [% of total cases]
highly probable 7 3.1 14 6.2
probable 33 14.6 19 8.4
possible 78 34.5 124 54.9
unlikely 71 31.4 33 14.6
excluded 37 16.4 36 15.9
WHO-UMC causality assessment system categories were assigned to CIOMS score categories as follows: certain=highly probable+probable; probable/likely=probable, (highly
probable); possible and possible/unclassified=possible; unlikely=unlikely, unclassified and unclassifiable=excluded.
doi:10.1371/journal.pone.0025221.t008
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be used to develop a balanced perspective that can be reasonable
validated. There is a need to improve the quality of data collected
and to develop an automised procedure for the careful assessment
and collation of spontaneous ADR reports that will permit the
effective detection of hitherto unknown adverse drug reactions – a
process known as ‘‘signal detection’’. The quality and practical
usefulness of spontaneous pharmacovigilance reporting systems is
dependent on the completeness of the reports and the validity,
reliability and overall plausibility of the data. The development of
novel algorithms / interrogation procedures used in pharmacov-
igilance will help to ascertain the plausibility and causality of
reported ADRs. Indeed, the current causality evaluation systems
(WHO and CIOMS) do not discriminate between genuine drug-
related adverse events and drug-drug interactions that result in
ADRs, but such interplay of different risk factors need to be
considered for an improved discriminatory power and overall risk
benefit assessment.
The road ahead
Our study exemplifies the gap between currently implemented
spontaneous ADR reporting systems and plausibility of causality
assessment. It is of paramount importance to develop simple
strategies in order to improve the content-quality of spontaneously
reported pharmacovigilance information based on patient factors
and a thorough drug history.
Vigorous and thorough causality assessment, as suggested in the
present study, has to be implemented into the national and local
pharmacovigilance routine and the daily clinical practise. It should
be noted that information on causality is required by regulatory
authorities and causality assessment is performed by the marketing
authorization holder; however this information frequently remains
incomplete and poorly validated and sometimes may be even lost
in the current pharmacovigilance process. Although a vast amount
of literature regarding various methods of data base management,
statistical analysis and signal detection algorithms is available, it is
still the input-quality and completeness of information that matters
(i.e. garbage in – garbage out!) and there appears to be still major
room for improvements.
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